Castle Biosciences presented new data showing that their DecisionDx-Melanoma test can identify higher-risk patients within a traditionally low-risk group of thin melanomas (T1a). The test combines gene expression profiling with clinical factors to provide personalized five-year recurrence-risk estimates, improving risk assessment beyond standard staging. This allows clinicians to tailor follow-up and treatment more precisely, potentially improving outcomes for patients who might otherwise be underestimated by traditional methods. The findings were shared at major dermatology conferences in 2026, supporting the test's clinical utility in melanoma management.
The DecisionDx-Melanoma test data is the subject here, with Pluang's Health sector market data providing context. For readers following Health stocks, 70 of 150 US stocks rose and 71 fell today. Notable moves include AHCO at USD 7.90 (+2.33%), MDLN at USD 39.97 (-2.30%), and DYN at USD 17.52 (-2.23%) with balanced order activity. This snapshot is as of Nov 11, 2026 17:11 WIB.
NRx Pharmaceuticals has begun selling a new preservative-free ketamine made in the U.S., addressing a shortage that has persisted since 2018. This ketamine uses innovative blow-fill-seal technology, eliminating the preservative benzethonium chloride,...
FLSmidth & Co. A/S announced its financial calendar for 2027, including key dates for the annual report, interim financial reports, and the annual general meeting. The company emphasizes its commitment to sustainability with its MissionZero goal to a...
Dimensional Fund Advisors Ltd. has filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc, totaling 12,054,886 shares as of November 10, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicatin...
Dimensional Fund Advisors Ltd. has filed a disclosure showing it holds a 1.61% stake in DCC Energy plc's ordinary shares as of November 10, 2026. The firm sold 42,998 shares recently at a price of £64.5585 each. This disclosure is part of regulatory ...
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
